Extracellular Vesicle-Mediated IL-1 Signaling in Response to Doxorubicin Activates PD-L1 Expression in Osteosarcoma Models

• Main Authors: Su Yati, Atiruj Silathapanasakul, Chakrarin Thakaeng, Mayuree Chanasakulniyom, Napat Songtawee, Sureerut Porntadavity, Peraphan Pothacharoen, Dumnoensun Pruksakorn, Prachya Kongtawelert, Pa Thai Yenchitsomanus, Theerawut Chanmee
• Other Authors: Siriraj Hospital
• Format: Article
• Published: 2022
• Subjects: Medicine
• Online Access: https://repository.li.mahidol.ac.th/handle/123456789/74730
• Institution: Mahidol University

The expression of programmed cell death ligand 1 (PD-L1) in tumors is associated with tumor cell escape from T-cell cytotoxicity, and is considered a crucial effector in chemoresistance and tumor relapse. Although PD-L1 induction has been observed in patients after chemotherapy treatment, the mechanism by which the drug activates PD-L1 expression remains elusive. Here, we identified the extracellular vesicles (EVs) as a molecular mediator that determines the effect of dox-orubicin on PD-L1 expression in osteosarcoma models. Mechanistically, doxorubicin dependently stimulates the release of extracellular vesicles, which mediate autocrine/paracrine signals in osteo-sarcoma cells. The recipient cells were stimulated by these EVs and acquired the ability to promote the expression of inflammatory cytokines interleukin (IL)-1β and IL-6. In response to doxorubicin, IL-1β, but not IL-6, allowed-osteosarcoma cells to promote the expression of PD-L1, and the elimi-nation of IL-1β/IL-1 receptor signaling with IL-1 receptor antagonist reduced PD-L1 expression. To-gether, these findings provided insights into the role of EV release in response to chemotherapy that mediates PD-L1 expression via the IL-1 signaling pathway, and suggested that the combination of a drug targeting IL-1 or PD-L1 with chemotherapy could be an effective treatment option for oste-osarcoma patients.